SciTech Development to Present at 2020 NYC Spring Oncology Investor Conference

GROSSE POINTE, Mich. - March 4, 2020 - PRLog -- SciTech Development, a clinical stage drug development company, will deliver a corporate presentation and meet with investors at the NYC Spring Oncology Investor Conference 2020. The conference will take place March 31 - April 1, 2020 at 1155 6th Ave, 22^nd Floor in New York City.

         Presenting SciTech's proprietary ST-001 nanoFenretinide technology at the conference will be Earle Holsapple (SciTech President) and Dr. Brian Leyland-Jones (SciTech Chief Medical Officer). Investors and interested parties are invited to request a meeting with SciTech Development during and after the conference through the One-on-One Meeting Space or via mobile phone: Earle Holsapple | +1-313-938-5517.

         SciTech is seeking funding to bring its lead product ST-001 nanoFenretinide to market for the treatment of T-cell non-Hodgkin's lymphoma (NHL) and small cell lung cancer (SCLC). ST-001 may be used as a standalone drug or as an ancillary treatment with immunotherapy. SciTech's product pipeline also includes treatment for several other cancer indications.

         The FDA has accepted SciTech Development's IND Application for ST-001 nanoFenretinide treatment of T-cell non-Hodgkin's lymphoma (NHL). The FDA has granted Orphan Drug Status for ST-001 in the treatment of two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).

Additional info regarding SciTech and its patented nanoparticle technology can be found at https://www.scitechdevelopment.com/.